MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ATOS — Atossa Therapeutics, Inc. Common Stock
NasdaqAtossa Therapeutics, Inc. Common Stock
$2.27
+0.32(+16.41%)
- O
- 1.96
- H
- 2.30
- L
- 1.96
- V
- 112.71K
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ATOS
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateNov 8, 2012
Employees14
Stock ExchangeNasdaq
Ticker SymbolATOS
Key Financial Statistics
| Market Cap | $18.96M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.70 - $33,480.00 |
| 52-Week Avg Volume | 105.1K |
| VWAP | $2.14 |
| Transactions | 903 |
| Total Recorded Bars | 3,494 days |